BMY Stock: Precision Medicine & Immunotherapy in Cancer Treatment

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Explore how Bristol-Myers Squibb pioneers cancer treatment using precision medicine & immunotherapy for improved patient outcomes and survival rates.

A decade ago, immuno-oncology revolutionized cancer therapy, leading to improved outcomes and longer survival rates for many patients. Bristol-Myers Squibb Co (NYSE: BMY) has been a pioneer in immunotherapy, particularly in developing dual immunotherapy combinations, and continues to research new, complementary therapies. 

One approach involves building upon existing therapies that overcome immune inhibition. Bristol Myers Squibb has explored multiple methods to address immune responses and leverage them against tumors. By targeting immune checkpoints like CTLA-4, PD-1, and LAG-3, researchers can release the "brakes" on T cells, enabling them to recognize and attack tumors. Combining LAG-3 with existing immunotherapies has shown promise, leading to the exploration of doublet and triplet combinations.

Another approach focuses on immunostimulatory therapies that directly stimulate the immune system. These therapies, such as those leveraging the IL-2 pathway, "step on the gas" of the immune system. Combining immunostimulatory therapies with existing therapies that overcome immune inhibition may enhance the immune system's response to cancer while maintaining a favorable safety profile.

The Impact of Precision Medicine on Cancer Research and Patient Outcomes

Precision medicine plays a crucial role in advancing new cancer therapies. Identifying biomarkers that indicate the efficacy of specific treatments for patients can help target therapies and improve outcomes. Bristol Myers Squibb is committed to a precision medicine approach and, with strategic research and development, aims to address the unmet clinical needs of cancer patients.

BullFrog AI Holdings, Inc. (NASDAQ: BFRG), a digital technology company leveraging machine learning to revolutionize precision medicine, has announced several key developments in recent weeks. The company filed its Form 10-K with the Securities and Exchange Commission (SEC) for the year ended December 31, 2022, rectifying a compliance notice from Nasdaq, and ensuring future filings will not face similar delays.

BullFrog AI has also formed a strategic partnership with the Sage Group, a leader in providing strategic and transactional advice to healthcare and life science companies. This partnership aims to advance BullFrog AI's Phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, and the company's preclinical prodrug asset. The market for glioblastoma treatment is projected to surpass $10 billion by 2030, according to a Vision Research Report.

The company has also acquired exclusive licenses from Johns Hopkins University for a novel formulation of mebendazole, which has been evaluated in two clinical trials for glioblastoma, and a novel prodrug of mebendazole with improved bioavailability. Additionally, the company announced a worldwide license agreement with Johns Hopkins University Applied Physics Laboratory for the use of patented technology powering its bfLEAP platform.

The bfLEAP platform, BullFrog AI's proprietary artificial intelligence platform, aims to streamline data analytics in therapeutics development, decrease overall development costs, and improve patient access to therapies. As a pre-revenue microcap stock, BullFrog AI is a potentially risky investment. 

On February 16, 2023, BullFrog AI announced the closing of its initial public offering (IPO), raising approximately $8.4 million in gross proceeds. The shares and tradeable warrants began trading on the Nasdaq Capital Market on February 14, 2023, under the symbols "BFRG" and "BFRGW," respectively. We previously covered the BullFrog AI IPO in one of our IPO Outlooks.

What's Next for Your Investment Portfolio?

To deepen your understanding and expand your investment strategies, consider exploring our investing guides on topics such as buying OTC and TSX stocks, finding investment opportunities, and the benefits of investing in gold.

Sign up for Investing Intel Newsletter

Check out our recent articles:

Our latest analysis section includes a variety of articles that may interest you. One such article is the OTC Top 50 for 2023, which can give you an insight into the top companies that you may want to invest in this year. If you are interested in the world economy, you can check out "The 30 Biggest Economies in the World" to learn more about the countries that are leading the global economy.

Additionally, we have also published "Why Invest in Gold" and "Is Gold a Good Investment in 2023?” to help you understand the benefits and risks of investing in gold. For investors interested in banking, "Reasons to Watch Bank Earnings in 2023" is a must-read to help you stay up-to-date with the latest financial trends.


In this article:


Author: Patricia Miller

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter